Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

190 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis.
Dawson R, Diacon A. Dawson R, et al. Among authors: diacon a. Expert Opin Investig Drugs. 2013 Jul;22(7):927-32. doi: 10.1517/13543784.2013.801958. Epub 2013 May 21. Expert Opin Investig Drugs. 2013. PMID: 23687915 Review.
AREAS COVERED: Recently, the first novel potential combination TB treatment regimen for both drug-sensitive and MDR TB incorporating a new nitroimidazole compound, PA-824 , was investigated in a Phase II proof-of-concept clinical trial. ...We will highlight how this …
AREAS COVERED: Recently, the first novel potential combination TB treatment regimen for both drug-sensitive and MDR TB incorporating a
Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.
Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald PR. Diacon AH, et al. Antimicrob Agents Chemother. 2007 Aug;51(8):2994-6. doi: 10.1128/AAC.01474-06. Epub 2007 May 21. Antimicrob Agents Chemother. 2007. PMID: 17517849 Free PMC article. Clinical Trial.
Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.
Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, De Marez T, van Heeswijk R, Kerstens R, Koul A, De Beule K, Donald PR, McNeeley DF. Rustomjee R, et al. Among authors: diacon ah. Antimicrob Agents Chemother. 2008 Aug;52(8):2831-5. doi: 10.1128/AAC.01204-07. Epub 2008 May 27. Antimicrob Agents Chemother. 2008. PMID: 18505852 Free PMC article. Clinical Trial.
Tibotec Medicinal Compound 207 (TMC207) is a novel diarylquinoline with a unique mode of action that targets mycobacterial ATP synthase. ...In summary, TMC207 demonstrated bactericidal activity with a delayed onset and was well tolerated, and no study drug-re …
Tibotec Medicinal Compound 207 (TMC207) is a novel diarylquinoline with a unique mode of action that targets mycobacterial ATP …
The diarylquinoline TMC207 for multidrug-resistant tuberculosis.
Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF. Diacon AH, et al. N Engl J Med. 2009 Jun 4;360(23):2397-405. doi: 10.1056/NEJMoa0808427. N Engl J Med. 2009. PMID: 19494215 Clinical Trial.
BACKGROUND: The diarylquinoline TMC207 offers a new mechanism of antituberculosis action by inhibiting mycobacterial ATP synthase. ...METHODS: In the first stage of a two-stage, phase 2, randomized, controlled trial, we randomly assigned 47 patients who had newly di …
BACKGROUND: The diarylquinoline TMC207 offers a new mechanism of antituberculosis action by inhibiting mycobacterial ATP synthase. .. …
Management of life-threatening haemoptysis in an area of high tuberculosis incidence.
Gross AM, Diacon AH, van den Heuvel MM, Janse van Rensburg J, Harris D, Bolliger CT. Gross AM, et al. Among authors: diacon ah. Int J Tuberc Lung Dis. 2009 Jul;13(7):875-80. Int J Tuberc Lung Dis. 2009. PMID: 19555538
RESULTS: Within a 7-month period, 101 consecutive patients were admitted. Seven were excluded and 12 died shortly after admission. ...
RESULTS: Within a 7-month period, 101 consecutive patients were admitted. Seven were excluded and 12 died shortly after admission. .. …
Direct comparison of the diagnostic yield of ultrasound-assisted Abrams and Tru-Cut needle biopsies for pleural tuberculosis.
Koegelenberg CF, Bolliger CT, Theron J, Walzl G, Wright CA, Louw M, Diacon AH. Koegelenberg CF, et al. Among authors: diacon ah. Thorax. 2010 Oct;65(10):857-62. doi: 10.1136/thx.2009.125146. Epub 2009 Dec 8. Thorax. 2010. PMID: 19996342 Clinical Trial.
METHODS: 89 patients (54 men) of meanSD age 38.716.7 years with pleural effusions and a clinical suspicion of tuberculosis were enrolled in the study. ...CONCLUSIONS: Ultrasound-assisted pleural biopsies performed with an Abrams needle are more likely to contain pleura and …
METHODS: 89 patients (54 men) of meanSD age 38.716.7 years with pleural effusions and a clinical suspicion of tuberculosis were enrol …
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.
Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, Donald PR, van Niekerk C, Whitney K, Rouse DJ, Laurenzi MW, Ginsberg AM, Spigelman MK. Diacon AH, et al. Antimicrob Agents Chemother. 2010 Aug;54(8):3402-7. doi: 10.1128/AAC.01354-09. Epub 2010 May 24. Antimicrob Agents Chemother. 2010. PMID: 20498324 Free PMC article. Clinical Trial.
PA-824 is a novel nitroimidazo-oxazine being evaluated for its potential to improve tuberculosis (TB) therapy. This randomized study evaluated safety, tolerability, pharmacokinetics, and extended early bactericidal activity of PA-824 in drug-sensitive, sputum smear-positiv …
PA-824 is a novel nitroimidazo-oxazine being evaluated for its potential to improve tuberculosis (TB) therapy. This randomized study …
Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents.
Diacon AH, Maritz JS, Venter A, van Helden PD, Andries K, McNeeley DF, Donald PR. Diacon AH, et al. Eur J Clin Microbiol Infect Dis. 2010 Dec;29(12):1561-5. doi: 10.1007/s10096-010-1043-7. Epub 2010 Sep 4. Eur J Clin Microbiol Infect Dis. 2010. PMID: 20820832 Clinical Trial.
Evaluation of early bactericidal activity (EBA) by the determination of a fall in viable colony-forming units (CFU) of Mycobacterium tuberculosis in sputum is a first step in the clinical study of new antituberculosis agents. ...Automated TTD could augment, or, in f …
Evaluation of early bactericidal activity (EBA) by the determination of a fall in viable colony-forming units (CFU) of Mycobacterium …
The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children.
Donald PR, Maritz JS, Diacon AH. Donald PR, et al. Among authors: diacon ah. Tuberculosis (Edinb). 2011 May;91(3):196-207. doi: 10.1016/j.tube.2011.02.004. Epub 2011 Mar 22. Tuberculosis (Edinb). 2011. PMID: 21429802 Review.
These results indicate that for equivalent RMP dosages adult patients reach a lower C(max) than adult volunteers and that adults, both volunteers and patients established on RMP reach higher C(max) values than children; children established on RMP require approximately twi …
These results indicate that for equivalent RMP dosages adult patients reach a lower C(max) than adult volunteers and that adults, bot …
Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial.
Friedrich SO, Venter A, Kayigire XA, Dawson R, Donald PR, Diacon AH. Friedrich SO, et al. Among authors: diacon ah. J Clin Microbiol. 2011 Aug;49(8):2827-31. doi: 10.1128/JCM.00138-11. Epub 2011 Jun 8. J Clin Microbiol. 2011. PMID: 21653771 Free PMC article.
We investigated the suitability of two novel sputum-based nucleic acid amplification methods for patient selection in a recent early bactericidal activity study. ...Xpert should be further explored as a surrogate measurement for sputum mycobacterial load....
We investigated the suitability of two novel sputum-based nucleic acid amplification methods for patient selection in a recent early …
190 results
Jump to page
Feedback